The DAC system and associations with multiple myeloma

por Ocio, Enrique M., San Miguel, Jesús F.
Publicado 2010

The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective

por San-Miguel, Jesus F., Einsele, Hermann, Moreau, Philippe
Publicado 2016

Is immunotherapy here to stay in multiple myeloma?

por Rodríguez-Otero, Paula, Paiva, Bruno, Engelhardt, Monika, Prósper, Felipe, San Miguel, Jesús F.
Publicado 2017

Measurable residual disease in multiple myeloma: ready for clinical practice?

por Burgos, Leire, Puig, Noemi, Cedena, Maria-Teresa, Mateos, María-Victoria, Lahuerta, Juan José, Paiva, Bruno, San-Miguel, Jesús F.
Publicado 2020

Deficient Spindle Assembly Checkpoint in Multiple Myeloma

por Díaz-Rodríguez, Elena, Álvarez-Fernández, Stela, Chen, Xi, Paiva, Bruno, López-Pérez, Ricardo, García-Hernández, Juan Luis, San Miguel, Jesús F., Pandiella, Atanasio
Publicado 2011

Immunophenotypic Characterization of Human Bone Marrow Mast Cells. A Flow Cytometric Study of Normal and Pathological Bone Marrow Samples

por Escribano, Luis, Orfao, Alberto, Villarrubia, Jesús, Díaz-Agustín, Beatriz, Cerveró, Carlos, Rios, Agustín, Velasco, José L., Ciudad, Juana, Navarro, José L., San Miguel, Jesús F.
Publicado 1998

Bone Marrow Mesenchymal Stem Cells for Improving Hematopoietic Function: An In Vitro and In Vivo Model. Part 2: Effect on Bone Marrow Microenvironment

por Carrancio, Soraya, Blanco, Belen, Romo, Carlos, Muntion, Sandra, Lopez-Holgado, Natalia, Blanco, Juan F., Briñon, Jesus G., San Miguel, Jesus F., Sanchez-Guijo, Fermin M., del Cañizo, M. Consuelo
Publicado 2011

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

por Richardson, Paul G., San Miguel, Jesus F., Moreau, Philippe, Hajek, Roman, Dimopoulos, Meletios A., Laubach, Jacob P., Palumbo, Antonio, Luptakova, Katarina, Romanus, Dorothy, Skacel, Tomas, Kumar, Shaji K., Anderson, Kenneth C.
Publicado 2018

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma

por Stadtmauer, Edward A, Weber, Donna M, Niesvizky, Ruben, Belch, Andrew, Prince, Miles H, San Miguel, Jesús F, Facon, Thierry, Olesnyckyj, Marta, Yu, Zhinuan, Zeldis, Jerome B, Knight, Robert D, Dimopoulos, Meletios A
Publicado 2009

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines

por Paíno, Teresa, Sarasquete, María E., Paiva, Bruno, Krzeminski, Patryk, San-Segundo, Laura, Corchete, Luis A., Redondo, Alba, Garayoa, Mercedes, García-Sanz, Ramón, Gutiérrez, Norma C., Ocio, Enrique M., San-Miguel, Jesús F.
Publicado 2014

Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development

por Herrero-Sánchez, Mª Carmen, Rodríguez-Serrano, Concepción, Almeida, Julia, San Segundo, Laura, Inogés, Susana, Santos-Briz, Ángel, García-Briñón, Jesús, Corchete, Luis Antonio, San Miguel, Jesús F., del Cañizo, Consuelo, Blanco, Belén
Publicado 2016

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease

por Garcia-Gomez, Antonio, Las Rivas, Javier De, Ocio, Enrique M., Díaz-Rodríguez, Elena, Montero, Juan C., Martín, Montserrat, Blanco, Juan F., Sanchez-Guijo, Fermín M., Pandiella, Atanasio, San Miguel, Jesús F., Garayoa, Mercedes
Publicado 2014

Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects

por Garcia-Gomez, Antonio, Ocio, Enrique M., Crusoe, Edvan, Santamaria, Carlos, Hernández-Campo, Pilar, Blanco, Juan F., Sanchez-Guijo, Fermin M., Hernández-Iglesias, Teresa, Briñón, Jesús G., Fisac-Herrero, Rosa M., Lee, Francis Y., Pandiella, Atanasio, San Miguel, Jesús F., Garayoa, Mercedes
Publicado 2012

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagn...

por San-Miguel, Jesús F., Echeveste Gutierrez, Maria-Asunción, Špicka, Ivan, Mateos, María-Victoria, Song, Kevin, Craig, Michael D., Bladé, Joan, Hájek, Roman, Chen, Christine, Di Bacco, Alessandra, Estevam, Jose, Gupta, Neeraj, Byrne, Catriona, Lu, Vickie, van de Velde, Helgi, Lonial, Sagar
Publicado 2018

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma

por Puig, Noemí, Flores-Montero, Juan, Burgos, Leire, Cedena, María-Teresa, Cordón, Lourdes, Pérez, José-Juan, Sanoja-Flores, Luzalba, Manrique, Irene, Rodríguez-Otero, Paula, Rosiñol, Laura, Martínez-López, Joaquín, Mateos, María-Victoria, Lahuerta, Juan-José, Bladé, Joan, San Miguel, Jesús F., Orfao, Alberto, Paiva, Bruno
Publicado 2021

Expression of p53 protein isoforms predicts survival in patients with multiple myeloma

por Rojas, Elizabeta A., Corchete, Luis A., De Ramón, Cristina, Krzeminski, Patryk, Quwaider, Dalia, García‐Sanz, Ramón, Martínez‐López, Joaquín, Oriol, Albert, Rosiñol, Laura, Bladé, Joan, Lahuerta, Juan José, San Miguel, Jesús F., González, Marcos, Mateos, María Victoria, Bourdon, Jean‐Christophe, Misiewicz‐Krzeminska, Irena, Gutiérrez, Norma C.
Publicado 2022

P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.

por Sánchez, Cristina De Ramón, Rojas, Elizabeta A, Misiewicz-Krzeminska, Irena, Cardona-Benavides, Ignacio J, Cuadrado, Myriam, Isidro, Isabel, Jose Calasanz, Maria, García-Sanz, Ramón, Rosiñol Dachs, Laura, Martinez-Lopez, Joaquín, Baldé, Joan, Lahuerta, Juan J, San Miguel, Jesus F, Mateos, Maria-Victoria, Corchete, Luis A, Gutierrez, Norma Carmen Gutierrez
Publicado 2023